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ABSTRACT 
Aim To evaluate the cost-effectiveness of needle and syringe programmes (NSPs) compared 
to no NSPs on hepatitis C virus (HCV) transmission in the United Kingdom. 
Design Cost-effectiveness analysis from NHS/ health-provider perspective, utilising a dynamic 
transmission model of HCV infection and disease progression, calibrated using city-specific 
surveillance and survey data, and primary data collection on NSP costs. The effectiveness of 
NSPs preventing HCV acquisition was based on empirical evidence. 
Setting UK settings with different chronic HCV prevalence among people who inject drugs 
(PWID): Dundee (26%), Walsall (18%), and Bristol (45%) 
Population PWID 
Interventions Current NSP provision is compared to a counterfactual scenario where NSPs 
are removed for 10 years and then returned to existing levels with effects collected for 40 
years.  
Measurements HCV infections, and cost per quality adjusted life year (QALY) gained through 
NSPs over 50 years   
Findings Compared to a willingness-to-pay threshold of £20,000 per QALY gained, NSPs were 
highly cost-effective over a time-horizon of 50 years and decreased the number of HCV 
incident infections. The mean incremental cost-effectiveness ratio was cost-saving in Dundee 
and Bristol, and £596 per QALY gained in Walsall, with 78%, 46% and 40% of simulations being 
cost-saving in each city, respectively, with differences driven by coverage of NSP and HCV 
prevalence (lowest in Walsall). Over 90% of simulations were cost-effective at the willingness-
to-pay threshold.  Results were robust to sensitivity analyses including varying the time-
horizon, HCV treatment cost and numbers of HCV treatments per year.   
Conclusions We projected NSPs avert HCV infections and are highly cost-effective in the UK 
and could be cost-saving to the NHS and other health care providers. NSPs will remain cost-
effective in the UK irrespective of changes in HCV treatment cost and scale-up, meaning that 
NSPs will continue to be an efficient strategy for preventing HCV transmission in the future. 
Abbreviations: 
HCV, Hepatitis C Virus; PWID, People who inject drugs; NSP, Needle and syringe programmes; 
IPED, image and performance enhancing drugs; OST, opioid substitution therapy; HCNSP, high 
coverage needle and syringe provision; QALY, quality adjusted life year;  ICER, incremental 
cost effectiveness ratio; WTP, willingness to pay; NMB, Net monetary benefit; HIV Human 
Immunodeficiency Virus  
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MAIN TEXT 
INTRODUCTION 
Hepatitis C virus (HCV) is a global public health issue, with an estimated 71 million people 
living with HCV[1, 2]. In the UK, approximately 200,000 are chronically infected, with 90% of 
new infections occurring among people who inject drugs (PWID)[3, 4]. Similar epidemics exist 
in other high-income settings[5]. To reduce the burden of HCV, it is crucial to reduce the 
incidence of HCV among PWID[6].  
In most settings, needle and syringe programmes (NSPs) are the primary intervention for 
reducing the transmission of blood borne viruses among PWID. NSPs provide sterile needles, 
syringes, injecting equipment, and other prevention and support services. There is good 
evidence that NSPs reduce injecting risk behaviours, and can prevent the acquisition of HCV 
and HIV amongst PWID[7-13].   
Previous research has shown that NSPs are a cost-effective intervention to reduce HIV 
incidence in multiple settings[14-21]. However, only two studies have considered their cost-
effectiveness in reducing HCV incidence[22, 23], with no studies from western Europe. In the 
UK, funding for NSPs is under threat due to budget cuts and shifting emphasis of drug policy 
to recovery and abstinence-based treatment programmes[24]. To improve the evidence base 
and inform policy choices, it is therefore important to assess the cost-effectiveness of NSP. 
We evaluated the cost-effectiveness of current levels of NSP provision on the transmission 
and disease burden of HCV in three UK settings, compared to a counterfactual of no NSP 
provision. 
METHODS  
Setting and Intervention 
The intervention considered was needle and syringe distribution services to prevent HCV 
transmission. NSPs in the UK can be provided through several modalities, including 
pharmacies, mobile vans, or fixed sites. The cost-effectiveness analysis focused on three 
settings in the UK: Bristol, Dundee and Walsall. These settings were selected based on 
differences in HCV prevalence, access to intervention coverage data, and feasibility of 
conducting a cost-effectiveness analysis.  Table 1 summarises key attributes of these settings. 
The chronic prevalence of HCV in the three settings (18-45%) ranges across the UK average of 
40%[3]. Coverage of harm reduction interventions varies from 72-81% for opioid substitution 
therapy (OST) and 30-57% for high coverage needle and syringe provision (HCNSP, taken to 
be at least one clean needle for every injection) compared with an average of 65% for OST 
and 48%-77% for HCNSP across UK[3, 25]. Although data is limited, PWID size estimates across 
our cities (750-2295) suggest they have moderate sized injecting populations[26, 27].  
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We collected cost data from NSP in each area. We only considered needle and syringe 
distribution to people who inject psychoactive drugs (such as opioids and stimulants; now 
denoted as PWID), not those injecting image and performance-enhancing drugs (IPEDs), as 
they have greater risk of HCV infection[28]. Other services provided by NSPs were not 
considered, including HCV testing, condom provision, and referral to community drug 
treatment programmes. In addition, we do not consider the impact of NSPs on HIV 
transmission.  
[Insert Table 1] 
Estimation of Costs 
The cost-effectiveness analysis uses a UK NHS (health and social care provider) 
perspective[29]. We estimated the incremental economic cost of NSP provision in each area 
for 2013-2014[30] in 2014 pounds sterling (GBP).  Cost data collection took place between 
March 2014 and July 2015 at several sites in each city, including the fixed-site NSP, two 
randomly selected pharmacy-based NSPs, and any additional NSP modalities operating in the 
area. Costs were estimated for the 2013-14 financial year. We took a bottom-up approach in 
collecting cost data, first estimating resource use and then valuing those resources according 
to their opportunity cost[31].  Resource use was measured using direct observation and 
reviewing programme records. We incorporated all resources: staff salaries, training, 
equipment, supplies, utilities, and building costs. Current market prices (2014 GBP) were 
applied to all resources; we estimated a ‘shadow cost’ for volunteer time or subsidized 
equipment. Overhead and support costs were estimated from programme records, and a 
portion allocated to NSP provision based on building space and management/support time. 
Human resource use was estimated through interviews and direct observations. Research 
costs were not included. All interviewees provided written consent, and the study received 
ethical approval by the London School of Hygiene and Tropical Medicine Research Ethics 
Committee (Reference: 6527). 
Cost inputs were defined as fixed costs (do not vary with output) and variable costs (vary with 
the level of output). Total costs for 2014 were estimated including all NSP modalities in each 
area, using their total fixed costs, plus an average variable cost for sterile injecting equipment 
(estimated per needle distributed to PWID).   
The costs of HCV care for HCV-related disease came from published estimates for the UK 
(Table S1)[32, 33], inflated to 2014 prices[34]. We assumed HCV treatment delivery costs for 
people currently injecting were 20% higher than for ex-injectors (extra nurse time)[35], and 
assumed treatment with 12-week direct acting antiviral (DAA) regimens after 2016[36] at a 
total drug cost of £39,600[37](Table S1). We assumed an annual cost for OST[38]. 
Model Description for Estimating Impact and Cost-effectiveness 
 
Page 5 of 21 
 
A dynamic model of HCV transmission and treatment was developed to estimate the impact 
of needle and syringe distribution in each city; described elsewhere[10] and in the 
supplementary materials. Briefly, the model incorporates HCV transmission among PWID and 
disease progression in PWID and ex-injectors. The model is a deterministic compartmental 
model using ordinary differential equations, stratified by injecting duration, intervention 
status (OST and/or NSP, or not), risk status (homeless and/or crack injecting or not), currently 
injecting or not, infection status and disease stage. New initiates to injecting are initially 
susceptible to HCV and become infected at a per-capita rate depending on their intervention 
state, injecting duration category, risk category and prevalence of HCV infection in the 
population.  Risk, whether increased (injecting duration and high-risk categories) or 
decreased (if on OST and HCNSP), is assumed to apply both to HCV transmission and 
acquisition. We assume random mixing between all subgroups. The model includes HCV 
disease progression (Fig 1)[39]. Following successful treatment (sustained viral response), 
continued slower progression occurs among those with compensated cirrhosis or more 
severe disease[40-42].  We account for re-infection amongst PWID and re-treatment.      
 
[Insert Figure1] 
 
Model parameterisation and calibration 
Epidemiological, demographic and harm reduction related parameters common to both the 
intervention and counterfactual scenarios for all three cities are in Table S2.  The model was 
further parameterized for each city using context-specific survey data and data from the 
literature, and calibrated using intervention coverage and HCV prevalence data in three steps.  
Firstly, the model was calibrated to PWID population size estimates using a PWID 
demographic sub-model without infection by varying the numbers initiating injecting each 
year and cessation rates. Secondly, the coverage of HCNSP and OST were fitted using a sub-
model that includes HCV transmission but no disease progression (allowing recruitment rates 
onto HCNSP and OST to vary). Thirdly, the HCV prevalence was fitted using the full model with 
disease progression by varying the transmission rate for those with no increased or decreased 
risk (see supplementary information for more details). Additional HCV prevalence and 
incidence data were used to validate the model projections (Tables S2, S3 and Fig S1).  Based 
on a recent pooled analysis of UK and Australian data, currently being on HCNSP or OST were 
assumed to reduce the risk of HCV transmission by 41% and 59%, respectively[30], with the 
risk reduced multiplicatively for those on OST with HCNSP.  Service data on the number of 
needles and syringes distributed in 2014 were used to estimate the proportion of injections 
utilising sterile injecting equipment (coverage) per PWID in each area to proxy the proportion 
of PWID on HCNSP. Survey data was used to estimate the proportion of PWID currently on 
OST.  
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The model was used to estimate the number of new infections and person-years spent in each 
HCV disease stage. Quality adjusted life year (QALY) utility weights came from the literature 
(Table S3)[32, 33], with the baseline quality of life for PWID being lower (0.85) than for other 
individuals (0.94)[33].  
For 2014, the model directly used the total estimated area-level costs of NSP. For other years, 
total annual costs were adjusted for changes in the number of PWID while assuming the same 
NSP cost (inflation adjusted) and coverage. Costs of HCV care and treatment were attached 
to each HCV disease stage. We assumed that half of all mild or moderate patients are 
diagnosed[3] and incur a cost, whereas all individuals in more progressed disease stages 
incurred care costs. All costs and QALYs were discounted at 3.5% per year[29]. 
To reflect parameter uncertainty, distributions were assigned to many model and cost 
parameters, which were randomly sampled to obtain 1000 model fits (see supplementary 
materials). 
Cost-effectiveness analysis 
For the NSP intervention scenario we assumed the coverage of HCNSP remained stable for 50 
years (2016-2065). In contrast, the counterfactual scenario (‘no NSP’) removed the costs and 
benefits of HCNSP for 10-years (2016-2025), and then re-instated them for 40 years (2026-
2065) to capture the future effects of the lack of HCNSP on HCV transmission and disease 
morbidity. A time-horizon of 50 years is standard practice to consider the lifetime of 
individuals impacted by the intervention and to fully capture the effects of HCV disease 
progression[29]. The incremental costs, disease outcomes and QALYs of NSPs compared to 
‘no NSPs’ were estimated over 2016-2065 for all 1000 model fits. Mean incremental cost 
effectiveness ratios (ICER=incremental costs/incremental effects) were compared to the 
£20,000 per QALY willingness-to-pay (WTP) threshold recommended by NICE[43].  Mean net 
monetary benefit (NMB = (incremental effectiveness*WTP threshold)-incremental costs) was 
also estimated for each area. Cost-effectiveness acceptability curves were plotted to 
determine the proportion of simulations that are cost-effective at the WTP threshold.   
Sensitivity analysis 
We carried out multiple sensitivity analyses to test the impact of assumptions on the ICER. 
These included assuming: no diagnosis for pre-cirrhotic chronic HCV disease (50% diagnosed 
in main analysis); same HCV treatment cost for people currently and no longer injecting 
(increased cost for people currently injecting in main analysis); 0% discount rate for costs and 
QALYs (3.5% in main analysis) and increased time-horizon of 100 years (50 years in main 
analysis). A threshold analysis also considered the minimum time-horizon over which NSP are 
cost-effective at a WTP threshold of £20,000 per QALY. To assess the likely impact of the 
changing landscape of HCV treatment we conducted analyses assuming 50% or 75% lower 
cost of HCV treatment from 2016; doubling and quadrupling the low HCV treatment rates in 
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Bristol and Walsall from 2016 (Dundee already has a high treatment rate); and quadrupling 
the treatment rates in Bristol and Walsall from 2016 while also reducing HCV treatment costs 
by 75%.   
A linear regression analysis of covariance [44] was undertaken to determine which parameter 
uncertainties contributed most to variability in incremental costs and QALYs.  
 
RESULTS 
Cost Analysis for NSP 
The size and cost of NSPs varied across the areas (Table 2), as did the number of needles 
distributed per PWID (Tables S4, S5).  Although the annual fixed costs of NSPs varied (£35,983-
£49,143 in Bristol to £8,672-£11,807 in Dundee), the average variable cost of injecting 
equipment was more consistent (median £0.26/needle in Bristol; £0.78/needle in Dundee). 
Overall, total estimated costs for 2014 range from a median of £79.45/PWID in Walsall to 
£159.21/PWID in Dundee. Uncertainty in NSP costs were largely driven by assumptions on 
the wastage of injecting equipment (Fig S2).  
[Insert Table2] 
 
Impact projections for NSP 
Compared to the counterfactual of no NSP over the next 10 years, projections suggest a 
median of 84-199 infections (8% of infections in Bristol and Walsall, 40% in Dundee) and 2-20 
deaths (1% of deaths in each area) would be averted in each area by continuing provision of 
NSP over this period, with benefits tracked over a further 40 years. Area-level differences in 
infections averted are due to variations in HCV treatment coverage (greater in Dundee), with 
wide uncertainty around the impact projections for each area being due to uncertainty in 
many model parameters, as discussed later.  Despite this uncertainty, all simulations 
projected deaths and infections averted for the NSP intervention scenario(Table S6).  
 
Cost-effectiveness analysis 
In all three settings, over the 50-year time-horizon, healthcare and treatment costs are lower 
in the baseline NSP scenario than in the no NSP counterfactual scenario (Table S7). Overall, 
the NSP scenario is cost saving in Bristol and Dundee, saving an average of £159,712 in Bristol 
and £2.5 million in Dundee over 50-years and gaining 502 and 195 incremental QALYs, 
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respectively (Table 3). In Walsall, the mean incremental cost of the NSP scenario is £114,442 
and gains 192 incremental QALYs (ICER £596 per QALY gained). Using a willingness-to-pay 
(WTP) threshold of £20,000 per QALY gained[29], this represents a NMB of £10.2 million in 
Bristol, £6.4 million in Dundee and £3.7 million in Walsall over 50 years.    
 
[Insert Table3] 
 
In each city, all simulations suggest the NSP scenario gains QALYs compared with the no NSP 
scenario.  In Dundee, most simulations (78%) suggest that NSP is cost saving; for Bristol and 
Walsall, 46% and 40% of simulations respectively are cost saving (Fig 2 and S3). Over 90% of 
simulations for each area are below the WTP threshold of £20,000 per QALY saved(Fig 2).   
 
[Insert Figure 2] 
 
Sensitivity analysis 
The sensitivity analyses indicated that our cost-effectiveness projections are robust to 
variations in parameter assumptions (Fig 3). Increasing the time-horizon to 100 years made 
the NSP scenario cost saving in all three cities, as did reducing the discount rate to 0% (costs 
and QALYs). The threshold analysis revealed that NSP becomes cost-effective in Bristol and 
Walsall if the time horizon is longer than 2- or 6-years post-intervention, respectively, while 
in Dundee it is cost-saving even with no years of follow-up. 
The highest ICERs for all three settings occurred when the cost of HCV treatment was reduced 
by 75% (Bristol and Walsall: £1518 and £2812 per QALY respectively, Dundee still cost-saving), 
but the mean ICERs remained well below the WTP threshold. Quadrupling the treatment rate 
improved the NSP ICER because of an added prevention benefit in terms of reducing re-
infections after successful HCV treatment (All three are cost-saving).   
 
[Insert Figure 3]  
 
Analysis of covariance (Fig S4) suggests that most of the variability in the incremental costs 
and QALYs in each setting is due to uncertainty in the efficacy of HCNSP (accounting for 52%, 
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50% and 27% of the variability in incremental costs and 80%, 73% and 20% of variability in 
incremental QALYs in Bristol, Walsall, and Dundee, respectively). The more effective HCNSP 
is at reducing HCV transmission the lower the incremental costs and higher the incremental 
QALYS (see Fig S5 for Bristol example). In Dundee, uncertainty in the prevalence of HCV also 
caused considerable variability (57% for incremental costs and 61% for incremental QALYs). 
A higher initial HCV prevalence results in lower incremental costs and higher incremental 
QALYS resulting in NSP being more cost-effective(see Fig S5). Otherwise, uncertainty in the 
cost of injecting equipment in Bristol and Walsall was an important cause of variability in 
incremental costs (10% and 28% respectively), while uncertainty in the coverage of HCNSP 
was an important cause of variability in the incremental QALYs for Bristol and Walsall (9% and 
5% respectively). 
 
DISCUSSION 
Main Findings 
Our analyses suggest that NSPs are highly cost-effective in the UK, and in some settings cost-
saving. We found variation in NSP costs across the three areas; there is no ‘standard’ structure 
for NSP services in the UK, and as such, each area had different service modalities and 
organisational structures. Differences in cost-effectiveness were also driven by variations in 
the impact achieved; fewest deaths were averted in Walsall due to its lower HCV 
prevalence[10], whilst more deaths and infections were averted in Bristol due to the higher 
HCV prevalence and larger PWID population. The largest proportion of infections averted was 
in Dundee where there is higher coverage of HCV treatment with HCNSP preventing re-
infection.  These differences did not affect our finding that NSPs are highly cost-effective. Our 
results were also robust to varied assumptions, including a lower cost for HCV treatment and 
a scale-up in HCV treatment, both of which are likely to occur in the near future.  
Comparison with Existing Evidence 
This is the first study evaluating the cost-effectiveness of NSPs in western Europe, and the 
first ever study to use empirical estimates of the efficacy of NSP for reducing HCV transmission 
risk[9]. Two other studies have considered the cost-effectiveness of NSP for averting HCV 
transmission; a study from Baltimore[22] estimated a cost of several hundred thousand 
dollars per averted HCV infection, and an Australian study indicated that  NSPs are cost-saving 
in preventing HIV and HCV infection due to averted healthcare costs[23]. Unfortunately, it is 
difficult to compare these findings to our projections. The US study did not collect primary 
cost data, but assumed a cost of US$5 per NSP client per day, contrasting with our estimates 
of £0.16-£0.42 per PWID per day.  The results of the Australian analysis were driven by the 
reduction in HIV transmission, which we did not include in our analysis.  
 
Page 10 of 21 
 
Strengths and Limitations 
A strength of our analysis lies in our use of primary cost data to reflect the ‘real-world’ costs 
of implementing NSPs in the UK. Although this ensures their relevance to the UK, 
uncertainties still existed due to gaps in the data. This was especially true for pharmacy-based 
NSP services, where detailed records were not available. These uncertainties in the cost of 
NSPs were included in our projections, and our findings were robust (i.e. were all cost-
effective) despite this. Standardised reporting of number of visits and numbers of needles 
and syringes distributed would facilitate comparison across different NSP sites, while 
implementing a system to record the number of individual clients reached would greatly 
facilitate estimation of unit costs and intervention coverage.   
A second potential weakness is that the assessment of health impact is based on model 
projections rather than study outcomes, and so caution is advised in the interpretation of our 
cost-effectiveness findings. This is common to all NSP evaluations, with our study improving 
on previous analyses by using empirical effect estimates for how NSP reduces HCV 
transmission risk rather than relying on self-reported behaviour change. We incorporated 
uncertainty in these empirical effect estimates in our analysis, as well as other parameters, 
which contributed to the large variation in both incremental costs and QALYs.  Uncertainty in 
the HCV prevalence in Dundee also contributed to the variation in incremental costs and 
QALYs in that setting. Despite this uncertainty, our results were robust, with over 90% of 
simulations under the UK willingness-to-pay threshold of £20,000 per QALY.  
Thirdly, there was uncertainty in the NSP coverage for each area. We used conservative 
service provision estimates of NSP coverage, which were lower or comparable to survey 
estimates from each setting, and also included uncertainty around these coverage estimates. 
More accurate estimates of syringe coverage are needed, as is consistent monitoring of NSPs 
and the services they provide[12]. 
Our approach to estimating the cost-effectiveness of NSPs was highly conservative: we did 
not incorporate other potential health benefits of NSP, or impact on people injecting IPEDs. 
We did not incorporate the health benefits associated with NSPs reducing the risk of HIV 
acquisition[45] because of difficulty in reliably modeling the transmission of an infection that 
is at low-levels. Incorporating HIV infections averted would improve our cost-effectiveness 
estimates[15, 46]. The analysis also did not include the health benefits from reducing 
injection-site infections and injuries [47], which may result through engaging the client in 
discussions about safer injecting behaviour. Our analysis also did not reflect the potential 
impact of NSPs in addressing the complex mental health and social support issues that PWID 
experience[48, 49]. When considering other potential benefits of NSPs, such as preventing 
HIV infection or skin and soft tissue infections, and addressing the psychosocial and welfare 
needs of PWID, NSPs are likely to be highly cost-saving. 
Implications and conclusions 
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NSP services are a highly effective low cost intervention to reduce HCV transmission, and in 
some settings are cost-saving. For example, in Dundee, we estimate long-term savings of up 
to 250% of the initial investment. In a recent analysis of public health interventions 
considered by NICE between 2006 and 2010, only 15% were cost-saving[50]. In this context, 
NSPs can be considered a very strong investment choice. 
These findings clearly point to the need to maintain funding for NSP services in the UK and 
elsewhere – while at the same time emphasising the need to strengthen the evidence for 
their effectiveness, including how the level of NSP provision and other NSP characteristics 
affect its efficacy.  Further work should also investigate what strategies or factors improve the 
cost-effectiveness of NSP and what can aid its scale-up. The findings also highlight the 
importance of joint commissioning and decision-making between agencies in the UK to meet 
the needs of local populations. Due to recent NHS reforms, the agencies responsible for 
commissioning NSPs are often different from those incurring any cost-savings. A co-financing 
approach would better represent the overall societal benefits of such an investment[51]. 
Different agencies may also need outcomes on different time frames; a lifetime horizon is 
recommended in NICE guidance for economic evaluations, while policy-makers and funders 
are more concerned with short-term outcomes. We found that shorter time-horizons 
remained cost-effective in Bristol and Walsall (after 2- and 6-years of follow-up), and cost-
saving in Dundee.  Short-term returns may also be accrued through psychosocial and welfare 
benefits of NSPs as mentioned above.   
These findings, whilst having limited generalisability for low and middle-income countries, are 
likely to be highly generalisable to other high-income settings with comparable HCV 
prevalence and harm reduction coverage such as Australasia and Western Europe[52], and 
therefore support the recommendations of WHO to develop and implement policies to 
support harm reduction among PWID[53]. These interventions should be delivered in 
combination with and complemented by prioritisation of drug treatment and expansion of 
HCV and HIV treatment[24].   
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Fig 1 Disease progression model 
 
 
 
F0-F4 are Metavir liver disease stages, with F0-F1 being mild disease, F2-F3 being moderate 
disease and F4 being compensated cirrhosis. Progression through the disease states occurs at 
a rate determined by the current disease state, as are the disease related death rates.  All 
states have a cessation rate from injecting drug use and a non-disease related background 
death rate.  Infection can occur from all disease states but are not shown for clarity. Those 
who spontaneously clear the infection are assumed to remain in the susceptible category. 
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Table 1 Coverage of OST and NSP and epidemiology of HCV among PWID in each city in 2014 
Baseline Characteristics  Bristol Dundee Walsall 
PWID population size (2011) 2295 (2025-2564) a 750 (675-825) b 1460 (1296-1623) c 
Total adult population size (aged 15-
59)[54] 
286,000 99,000 170,898 
Prevalence of current injecting drug 
use in adult population (%) 
0.8 0.75 0.85 
Chronic HCV Prevalence in PWID 
population 
45% (40-50%) d 26% (19-32%) e 18% (11-26%) d 
Proportion of PWID on OST 81% (77-86%) f 73% (65-79%) e 72% (61-82%) d 
Proportion of PWID with HCNSP (from 
service provision calculation) 
57% (38-82%) d 49% (34-79%) e 30% (21-42%) d 
Number PWID treated for HCV per 
year 
18 g 40 h 2 i 
a adjusted from [26]; b local estimate adjusted from [27]; c unpublished PWID prevalence for West 
Midlands; d Data extracted from unlinked anonymous monitoring survey [4]; e data extracted from 
Needle Exchange Surveillance Initiative [55]; f Mills, 2012 [56]; g Martin, 2015 [57]; h from 2015, 
personal communication John Dillon (Professor of Hepatology and Gastroenterology); i assumed 
similar rate per infected PWID as Bristol as conservative estimate; HCNSP high coverage needle and 
syringe provision; PWID people who inject drugs; OST, opioid substitution therapy; HCV, hepatitis C 
virus 
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Table 2 NSP related costs for PWID by city in 2014 GBP: Inputs for the model  
  
Total Needles distributed 
Total Annual 
Fixed Costs 
Average Variable 
Cost per Needle 
Total Annual Cost 
 
City Median Min Max Median Min Max Median Min Max Median Min Max 
Bristol 820,593 786,540 844,650 £44,142 £35,983 £49,143 £0.26 £0.15 £0.41 £262,762 £147,761 £391,409 
Dundee 142,098 138,250 145,770 £10,159 £8,672 £11,807 £0.78 £0.37 £1.19 £120,797 £62,123 £180,050 
Walsall 231,457 225,270 237,110 £21,068 £16,321 £26,319 £0.45 £0.20 £1.03 £110,715 £66,667 £153,667 
(for more information on derivation see supplementary information and [30]); NSP, needle 
and syringe provision; PWID, people who inject drugs. 
  
Table 3 Cost-effectiveness results: average total costs (2014 GBP), QALYs and incremental 
effectiveness ratios for the baseline NSP scenario compared with the no NSP scenario over 50 
years  
 
Total Cost Incremental 
Cost 
Total 
QALYs 
Incremental 
QALYs 
Mean ICER NMB 
Bristol 
      
no NSP £304,157,179 
 
187,663 
   
NSP £303,997,467 -£159,712 188,165 502 dominant £ 10,201,117 
Dundee 
      
no NSP £94,951,896 
 
83,904 
   
NSP £92,455,470 -£2,496,426 84,099 195 dominant £ 6,390,222 
Walsall 
      
no NSP £153,697,867 
 
142,702 
   
NSP £153,812,309 £114,442 142,894 192 £596 £   3,722,890 
QALY, quality adjusted life year; ICER, incremental cost effectiveness ratio; NMB, net 
monetary benefit; NSP, needle and syringe programmes. 
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Figure 2 Cost-effectiveness acceptability curves for each city 
 
Fig 3 Univariate Sensitivity Analysis 
Bristol 
 
Dundee 
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Walsall 
 
ICER, incremental cost effectiveness ratio; QALY, quality adjusted life year 
 
Supporting Information 
S1 Appendix. Technical Supplement 
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